Kura Oncology reported $5.8 million in net sales of KOMZIFTI (ziftomenib) in its first full quarter of commercialization, showing strong early adoption with 85 new patient starts and broad payer coverage over 93%. The company is advancing multiple clinical trials for ziftomenib in acute myeloid leukemia (AML), including ongoing Phase 3 frontline and combination studies, with several data readouts expected in 2026. Kura also presented promising data for its solid tumor drug darlifarnib and expects to sustain growth through commercial execution and clinical milestones. The company holds $580.8 million in cash and anticipates collaboration payments to fund development through pivotal trial results expected in 2028.
Toescoin, a memecoin on the Solana blockchain, announced talks with a major Japanese venture capital firm interested in investing up to $250,000 over time. This engagement aims to provide both funding and strategic support as Toescoin expands its pre...
A new patent application reveals a quantum AI project creating humanoid robots that can carry a person's 'digital DNA' to live alongside humans for centuries. This technology, part of a federally registered clinical trial, allows families to preserve...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging the company may have provided misleading business information to investors in its stock-based mutual funds. Investors who purchased Pu...
Lido DAO reported a temporary accounting error that understated stETH staking yields because a 32 ETH validator deposit was delayed in the reporting process. This issue was due to timing in the accounting snapshot and did not affect actual validator ...
Baker Hughes announced its Q2 2026 results with $10.5 billion in orders, including a record $7.1 billion in Industrial & Energy Technology (IET) orders, and $6.7 billion in revenue. Despite geopolitical challenges in the Middle East, the company achi...
